News | July 19, 2007

Fewer Stents Implanted in June

Source: Wall Street Journal Online

July 20, 2007 - U.S. doctors implanted fewer coronary stents in June than any other month in the last year, according to a market researcher, indicating that medical studies critical of the devices appear to be having a sustained impact.

Stents are tiny scaffolds that prop open clogged arteries. Doctors flocked to them until late last year because they quickly relieve the chest pains and shortness of breath caused by a blocked artery. Last year, Americans spent more than $14 billion on stent procedures, with doctors implanting about 130,000 stents a month, according to various estimates.

But data from Goodroe Healthcare Solutions LLC, of Norcross, Ga., which surveys 75 U.S. hospitals with catheterization facilities for stenting, indicated that rate has significantly slowed. According to Goodroe, doctors in June performed fewer artery-inflating angioplasties - 11 percent below January levels. Fewer of those procedures involve a stent - 92 percent, down from 94 percent in January. And doctors in June used about 1.48 stents per procedure, down 4 percent from January. Those numbers indicate stent usage, in total, fell about 16 percent. (See more data from Goodroe.)

Goodroe didn't provide usage numbers in units of stents. In the past, its numbers have largely agreed with figures released by manufacturers and market researchers.

In late March, the New England Journal of Medicine published a study indicating that patients with mild chest pains could safely delay stenting in favor of treatment with drugs. Some of those patients may return for stenting later in the year if their pain persists.

Stent use has also been hurt by studies linking the most popular and expensive kind -- those coated with drugs to prevent reclogging -- with blood clots more than a year after implantation. In response, doctors have shifted back to older, bare-metal stents.

That has been good news for Abbott Laboratories, whose U.S. sales of bare-metal stents were up 179 percent in the last year. But the makers of drug-coated stents - Johnson & Johnson, whose U.S. stent sales fell 41 percent and Boston Scientific Corp., which reports its quarterly results today - have been hit hard. Boston Scientific and Abbott said they predicted an eventual recovery in the market. J&J declined to comment.

For more information: http://online.wsj.com/article/SB118490323731372724.html?mod=djemHL

Or write to Keith J. Winstein at [email protected]

Related Content

Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...